Posted on October 15th, 2014 by
Based on recently analyzed data from a retrospective analysis of commercial insurance claims, rates of cancer are higher in patients with psoriasis and that some anti-psoriatic drugs may pose a higher risk than others.
Dr. Alexa B. Kimball of Massachusetts General Hospital reported at the American Academy of Dermatology summer meeting that rates for all cancers were similar among patients undergoing different psoriasis treatments, with the exception of nonmelanoma skin cancer and lymphoma.
Rates for these two cancers appeared more variable but were still above those in the general public. Doctors believe that the increased cancer risk may be associated with the chronic inflammation characteristic of psoriasis and potentially exposure to some psoriasis therapies.
The researchers evaluated the risk of cancer by reviewing data from insurance claims databases for patients with a diagnosis of and at least one prescription claim for etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), ustekinumab (Stelara), nonbiologic therapies, or phototherapy.
Patients with psoriasis had a 5-year malignancy rate of 115.5 cases/10,000 person-years, compared with 96/10,000 person-years for the general population. Excluding nonmelanoma skin cancer and lymphoma the rates were similar across treatment groups: etanercept (100.2/10,000), adalimumab (94.6/10,000), infliximab (138.1/10,000), ustekinumab (100.6/10,000), nonbiologics (116.8/10,000), and phototherapy (117.3/10,000).
Nonmelanoma skin cancer was far and away the most common malignancy in psoriasis patients, occurring at a rate of 147.2/10,000 person-years in psoriasis patients compared to only 94.2/10,000 person-years among the general public. Rates were highest in patients treated with adalimumab (234.2/10,000 person-years) and ustekinumab (233.3/10,000) and lowest in those treated with etanercept (155.9/10,000).
Rates of lymphoma were also higher in psoriasis patients than the general public (11.1/10,000 vs. 6.6/10,000). Rates of this hematologic cancer were highest with ustekinumab (25.1/10,000) and lowest with etanercept (6.9/10,000).
The study author, Dr. Kimball concluded that these large database queries continue to be reassuring that most therapies used in the management of psoriasis are not changing the risk for common cancers, excluding lymphoma and skin cancer. Patients with psoriasis should ensure that the benefits of therapy outweigh any risks including that of developing a cancer. Longer follow up will better define the relationship between these anti-psoriatic drug therapies and cancer.
Copyright © 2014 CancerConnect. All Rights Reserved.
You must be logged-in to the site to post a comment.